Blood, tissue and organ screening

05 March 2014

This session will explore the development and commercialisation of a range of technologies intended to reduce the risk of transmission of Creutzfeldt Jakob disease (CJD) via medical procedure. The panel will comprise of representatives of commercial and academic research groups involved in the development of these technologies.

Evidence hearing 

Wednesday 5 March 2014
Grimond Room, Portcullis House

At 9.15 am

  • Professor John Collinge, Director, MRC Prion Unit and Professor of Neurology at the UCL Institute of Neurology
  • Dr Steven Burton, Chief Executive, ProMetic Biosciences Ltd
  • Dr Kelly Board, Technical Specialist, DuPont Chemicals and Fluoroproducts
  • Dr Alex Raeber, Head of Research and Development, Prionics AG
  • Nigel Talboys, Global Director of Blood Safety and EMEA Director of Public Policy and Government Affairs, Terumo BCT

Further evidence sessions will be announced in due course.

Further information

Image: iStockphoto 

More news on: Parliament, government and politics, Parliament, Science and technology, Research and innovation, Science, Health services and medicine, House of Commons news, Commons news, Committee news

Share this page